ReviewAmerican journal of human genetics2025
Tackling a disease on a global scale, the Global Parkinson's Genetics Program, GP2: A new generation of opportunities.
Review in American journal of human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Global research synergy: Advancing fundamental Parkinson's research through international collaboration.Journal of Parkinson's disease · 2026Review
- Collaborative Genomics for Dystonia in Central and Eastern Europe: Successes Achieved, New Frontiers Ahead.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Large-scale functional annotation establishes a reference framework for humanmedRxiv : the preprint server for health sciences · 2026Article
- Mapping the Parkinson's pandemic: Unveiling and addressing the global burden.Journal of Parkinson's disease · 2026Review
- The Global Parkinson's Genetics Program (GP2): Advancing genetic discovery and capacity building worldwide.Journal of Parkinson's disease · 2026Review
- Bridging global diversity gaps in Parkinson disease research.Nature reviews. Neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The need for more diversity in research is a widely recognized problem, especially in the genetics and genomics fields. While resolving this problem seems straightforward by recruiting and sequencing research participants from underrepresented populations, implementing an effort like this is complex operationally. Key considerations include ensuring equity, building capacity, and creating a sustainable research collective that works collaboratively to address local and global questions in research. Here, we provide a roadmap detailing how the Global Parkinson's Genetics Program (GP2) is tackling the lack of diversity in Parkinson disease (PD) genetics research and also reflect on 5 years of progress. GP2 aims to be a global hub facilitating subject recruitment, sample collection, data generation, harmonization, and sharing. It also acts as a centralized target discovery hub for PD genetics worldwide. The underlying tenets of GP2 center on transparency, the democratization of data and discovery, training and career support, providing (or generating) actionable results, and creating a functional collective of PD researchers worldwide. GP2 is working with 275 research groups worldwide. There are data and samples from 265,000 subjects currently committed to the program as of May 2025. We discuss the lessons learned in this process and highlight what we view as the emerging opportunities that the program will aim to target over the next period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.